If you would like to automatically receive our news releases, financial alerts and event alerts we offer you two distinct and automated options.
Sign up to receive our news releases, financial alerts and event alerts via email. The information will come to your email as body text within the message. You may unsubscribe at any time.
If you use an RSS Reader, you may add our site update feed to your reader to receive updates. You may unsubscribe at any time.
NT219 is a first-in-class drug candidate with high affinity and selectivity to its target proteins Data show that even a short exposure of cancerous cells to NT219 was sufficient to trigger...